Cerecor Inc.
also invests · investor profileBaltimore, US · Founded 2011 · 51 employees on LinkedIn · 3 known investors
Find your way into Cerecor Inc.
411 people in our graph share verified history with the Cerecor Inc. team — schools, employers, funds. One of them is your warm intro.
Ashley Keatingunlockedknows James Vornov · together at Medpace (overlapped)
knows the team · via Medpace
knows the team · via Infonautics, Inc. (NASDAQ: INFO)
×2knows the team · via University of Virginia
knows the team · via Rutgers University
knows the team · via Old Dominion University
Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.
Founders & leadership
Cerecor Inc. was founded in 2011 by Blake M. Paterson.
BM
Blake M. PatersonFounder
MM
Mariam MorrisinExecutiveExecutive Officer at Cerecor Inc. (which operates Avalo, a clinical-stage biotech company developing therapeutics for immune-mediated inflammatory diseases). Morris has more than 25 years of experience in business strategy, BioPharma operations, SEC reporting, and investor relations.
RM
Ronald MarcusinExecutiveRonald Marcus held leadership positions including CMO at Cerecor and Spinifex, VP of Research and Development at Supernus, CMO at Terran Biosciences, and SVP of Medical at Karuna Therapeutics where he worked on the KarXT antipsychotic program; most recently he was at BMS working on the KarXT lifecycle management program. His background spans drug development across psychiatry, neurology, and pain conditions.
UH
Uli HacksellExecutive
JK
John KaiserinExecutive
JV
James VornovinExecutive(which operates Avalo, a clinical-stage biotech company developing IL-1β pathway therapeutics). He has held roles in academic research and clinical development at companies of varying sizes, with extensive experience across CNS therapeutic areas including stroke, neurodegeneration, and pain, as well as expertise in adaptive trial design and pharmacokinetic/pharmacodynamic modeling.
RM
Reza MazhariinExecutive
FF
Federica F. O'BrieninExecutiveFederica F. O'Brien is an Executive Officer at Cerecor Inc. (which develops Avalo, a clinical-stage biotechnology company focused on IL-1β pathway therapeutics for inflammatory diseases). She has held CFO and COO roles at private and public life sciences and technology companies, and spent 15 years in accounting, audit, tax and consulting roles at PwC and other public accounting firms.
BH
Bernadine Heather FraserExecutive
SR
Sharon RowlandinExecutiveShe has extensive experience in regulatory strategy and investigational product development for biologics, peptides, and small molecules across multiple therapeutic areas, including FDA and EMA interactions, IND filings, and NDA/BLA submissions.
Board
IB
Isaac BlechBoard director
MP
Magnus PerssonBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$152.9M disclosed across 4 rounds · 2014–2024
▶$130.6MraisedApr 2024 · 25 investors · BiotechnologyRule 506(b)
▶$130.6MraisedApr 2024 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- June Almenoff, M.D., Ph.D.Director
- Mitchell ChanDirector
- Jonathan Goldman, M.D.Director
- Aaron KantoffDirector
- Gilla Kaplan, Ph.D.Director
- Magnus Persson, M.D., Ph.D.Director
- Samantha TruexDirector
- Christopher SullivanExecutive Officer
- Garry Neil, M.D.Executive Officer, Director
- Offering amount
- $200M
- Amount sold
- $130.6M
- Finders' fees
- $6.9M
- Placement agents
- Oppenheimer & Co. Inc.
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMay 2017 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedMay 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- EUGENE A. BAUERDirector
- ISAAC BLECHDirector
- PHIL GUTRYDirector
- MAGNUS PERSSONDirector
- ULI HACKSELLExecutive Officer, Director
- JOHN KAISERExecutive Officer
- THOMAS AASENDirector
- MARIAM E MORRISExecutive Officer
- RONALD MARCUSExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedSep 2016 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedSep 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac BlechDirector
- Eugene BauerDirector
- Phil GutryDirector
- Thomas AasenDirector
- Mariam MorrisExecutive Officer
- Behshad SheldonDirector
- Ronald MarcusExecutive Officer
- Uli HacksellExecutive Officer, Director
- Magnus PerssonDirector
- John KaiserExecutive Officer
- Offering amount
- $15M
- Amount sold
- $1M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.3MraisedJul 2014 · 13 investors · BiotechnologyRule 506(b)
▶$16.3MraisedJul 2014 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Magnus PerssonDirector
- James VornovExecutive Officer
- Isaac BlechDirector
- Blake M. PatersonExecutive Officer, Director
- Reza MazhariExecutive Officer
- Frank TortiDirector
- Eugene A. BauerDirector
- Federica F. O'BrienExecutive Officer
- Bernadine Heather FraserExecutive Officer
- Sharon RowlandExecutive Officer
- Mayukh SukhatmeDirector
- Sol J. BarerDirector
- John KaiserExecutive Officer
- Offering amount
- $33.3M
- Amount sold
- $16.3M
- Finders' fees
- $300K
- Proceeds to insiders
- $755K
- Placement agents
- Trout Capital LLC
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Cerecor Inc. do?
- Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.
- Who founded Cerecor Inc.?
- Cerecor Inc. was founded by Blake M. Paterson in 2011.
- Who are Cerecor Inc.'s investors?
- Cerecor Inc.'s investors include New Enterprise Associates (NEA), OrbiMed, PETRICHOR SCION THERAPEUTICS.
- How much funding has Cerecor Inc. raised?
- Cerecor Inc. has disclosed $152.9M raised across 4 rounds.
- Where is Cerecor Inc. headquartered?
- Cerecor Inc. is headquartered in Baltimore, US.